GlassScriptPhysician profile
Kathy Christman
NPI 1215932645
$614.91
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $279 · 2021: $320 · 2022: $16.11.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adaptive Biotechnologies Corporation | $145.76 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $140.52 | 2019-2022 | |
| Kite Pharma, INC. | $94.26 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $71.09 | 2019 | |
| Pfizer INC. | $36.17 | 2019-2021 | |
| Gilead Sciences, INC. | $34.53 | 2021 | |
| Novartis Pharmaceuticals Corporation | $33.32 | 2021 | |
| Daiichi Sankyo INC. | $24.34 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.02 | 2021 | |
| Merck Sharp & Dohme LLC | $13.90 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathy Christman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.